ABSTRACT
Background and Aims Cumulating observations have indicated that patients with coronavirus disease (COVID-19) undergo different patterns of liver impairment. We performed a meta-analysis of published liver manifestations and described the liver damage in COVID-19.
Methods We searched PubMed, Google Scholar, Embase, Cochrane Library, medRxiv, bioRxiv, and three Chinese electronic databases through April 18, 2020, in accordance with the Preferred Reporting Items for Meta-Analyses. We analyzed pooled data on liver chemistries stratified by COVID-19 severity using a fixed or random-effects model.
Results In the meta-analysis of 37 studies, which included a total of 6,235 patients, the pooled mean alanine aminotransferase (ALT) was 36.4 IU/L in the severe COVID-19 cases and 27.8 IU/L in the non-severe cases (95% confidence interval [CI]: − 9.4 to − 5.1, p < 0.0001). The pooled mean aspartate aminotransferase (AST) was 46.8 IU/L in the severe cases and 30.4 IU/L in the non-severe cases (95% CI: − 15.1 to − 10.4, p < 0.0001). Furthermore, regardless of disease severity, the AST level is often higher than the ALT level. Compared with the non-severe cases, the severe cases tended to have higher γ-glutamyltransferase levels but lower albumin levels.
Conclusions In this meta-analysis, we comprehensively described three patterns of liver impairment related to COVID-19, namely hepatocellular injury, cholestasis, and hepatocellular disfunction, according to COVID-19 severity. Patients with abnormal liver test results are at higher risk of progression to severe disease. Close monitoring of liver chemistries provides an early warning against disease progression.
Lay Summary Data on abnormal liver chemistries related to coronavirus disease (COVID-19) are cumulating but are potentially confusing. We performed a meta-analysis of 37 studies that included a total of 6,235 patients with COVID-19. We noted that patients with abnormal liver test results are at higher risk of progression to severe disease and close monitoring of liver chemistries provides early warning against disease progression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China No.81871645 (JSP). The funding source did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mails: Xuan Dong 362485659{at}qq.com
Dan-Yi Zeng 1184359451{at}qq.com
Yan-Yan Cai 474349346{at}qq.com
Wei-Ming Chen 345173327{at}qq.com
Qing-Qing Xing 582398903{at}qq.com
Yan-Dan Ren 916659998{at}qq.com
Mei-Zhu Hong 546777397{at}qq.com
Jin-Shui Pan j.s.pan76{at}gmail.com
Data Availability
NA